Cravath, Sullivan & Cromwell Drive J&J's $16.6B Abiomed Buy
Johnson & Johnson will buy cardiovascular-focused medical technology company Abiomed for $380 per share, amounting to a $16.6 billion acquisition guided by Cravath Swaine & Moore LLP and Sullivan & Cromwell...To view the full article, register now.
Already a subscriber? Click here to view full article